N/A N=430 Implementation of a Transcutaneous Bilirubinometer
Neonatal Jaundice · Hyperbilirubinemia
Primary: Number of Blood Tests for Bilirubin Measurement (Before the Potential Start of Phototherapy). — 0; 1 blood tests for bilirubin
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=91 Stannsoporfin With Light Therapy for Newborn Babies With Jaundice
Jaundice, Neonatal · Hyperbilirubinemia, Neonatal
Primary: Total Serum Bilirubin (mg/dL) — 9.82; 9.97; 9.92; 8.48 mg/dL — p==0.0000021
N/A N=447 Treatment of Neonatal Jaundice With Filtered Sunlight Phototherapy: Safety and Efficacy in African Neonates
Jaundice, Neonatal
Primary: Safety of Phototherapy — 268; 325 treatment days
N/A N=99 Breastfeeding Support Intervention in Jaundiced Infants
Jaundice · Breastfeeding
Primary: Number of Participants Exclusively Breastfeeding at 3 Months, or 3 Months Corrected if the Infant Was Born Prematurely — 22; 24 Participants — p=0.40
N/A N=174 Filtered Sunlight Phototherapy to Treat Significant Jaundice: Safety and Efficacy in Neonates
Jaundice, Neonatal
Primary: Efficacy of Phototherapy — 116; 135 treatment days
N/A N=103 Transcutaneous Bilirubinometry in Neonates With Bilicare System
We Will Focus on Assessing the Clinical Performance of the BiliCare Device
Primary: BiliCare TcB Result Compared to TSB Result — 8.46; 7.93; 7.83 mg/dL
Phase 4 N=92 Efficacy of High-dose Intravenous Immunoglobulin Therapy for Hyperbilirubinemia Due Rh Hemolytic Disease
Hyperbilirubinemia · Erythroblastosis, Fetal
Primary: Need of Exchange Transfusion — 6; 7 participants — p=0.765
N/A N=113 Transcutaneous Bilirubinometry in Neonates With the Bilicare System
Transcutaneous Bilirubinometry
Primary: In This Study, the Investigators Plan to Test the Performance of a Novel Transcutaneous Device (BiliCareTM) to Screen for Bilirubin Levels at Postnatal Age of 12 to 48…
N/A N=111 Transcutaneous Bilirubinometry in Neonates With the BiliCare System Compared to the Invasive TSB Test
We Will Focus on Assessing the Clinical Performance of the BiliCare Device
Primary: BiliCare TcB Result Compared to TSB Result — 8.0; 7.3 mg/dL
N/A N=44 Characterization of Pre-Term Neonatal Skin
Skin Disorder
Primary: Bilirubin Concentration From Non-invasive Diffuse Reflectance Spectroscopy (DRS) vs BiliChek — 0.814386451; 0.85422779; 0.67588721; 0.79293382 Correlation Coefficient…
N/A N=79 Glycerin Suppositories to Reduce Jaundice in Premature Infants
Idiopathic Hyperbilirubinemia · Neonatal Hyperbilirubinemia · Prematurity
Primary: Total Number of Hours of Required Phototherapy — 72; 61 hours
N/A N=203 BiliCam Clinical Validation Study
Newborn Jaundice
Primary: BCB - TSB Correlation — 0.82 correlation coefficient — p=<.001
N/A N=624 Determining Prevalence of Acute Bilirubin Encephalopathy in Developing Countries
Hyperbilirubinemic Encephalopathy
Primary: Bilirubin Induced Neurologic Dysfunction II Score (BIND II) — 1 units on a scale
N/A N=21 Detecting Neonatal Hypoglycemia Using Real-Time Continuous Glucose Monitoring (CGM)
Neonatal Hypoglycemia
Primary: Sensor-detected Hypoglycemia — 5; 1 events
Phase 2 N=50 Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes in Newborn Brain Injury (NEATO)
Hypoxic-ischemic Encephalopathy · Neonatal Encephalopathy · Birth Asphyxia
Primary: Markers of Organ Function — 10; 6; 9; 12 participants
Phase 4 N=52 Early Sodium Intake in Preterm Newborns
Hyponatremia · Premature
Primary: Hyponatremia — 6; 1 Participants — p=0.71
Phase 4 N=66 The Effect of Lipid Emulsions on Free Fatty Acids and Free Bilirubin in Premature Newborns
Prematurity
Primary: Free Bilirubin (UB) Serum Levels — 10.5; 9.4 Nanomoles/Liter (nM)
N/A N=168 Preemie Hypothermia for Neonatal Encephalopathy
Infant, Newborn · Hypoxia, Brain · Hypoxia-Ischemia, Brain
Primary: Death or Moderate or Severe Disability — 29; 20 Participants
Phase 3 N=40 Prospective Randomized Clinical Trial of Intravenous Lipids and Cholestasis
Parenteral Nutrition Associated Cholestasis
Primary: Number of Participants With Parenteral Nutrition Associated Cholestasis — 6; 6 Participants — p=0.94
N/A N=63 Prospective Research in Infants With Mild Encephalopathy
Hypoxic-Ischemic Encephalopathy · Brain Injury · Neonatal Seizure
Primary: Percentage of Infants With Evidence of Neurological Dysfunction, Brain Injury and/or Abnormality. — 28 Participants
Phase 1 N=21 A Pilot Study of Moderate Hyperbilirubinemia in Type 1 Diabetes Mellitus
Type 1 Diabetes Mellitus
Primary: Change in Brachial Artery Diameter — -0.93 percentage of dilation
N/A N=65 Utility of Placental/Umbilical Cord Blood in Early Onset Neonatal Sepsis in Very Low Birth Weight Infants
Preterm Infant · Early-Onset Neonatal Sepsis · Umbilical Cord
Primary: White Blood Cell Count (WBC) (1) — 8257 ratio of cells/mm3
N/A N=136 Low Dose Parenteral Fat for Prevention of Parenteral Nutrition Associated Cholestasis in Preterm Neonates
Parenteral Nutrition-Associated Liver Disease
Primary: The Presence of Cholestasis at Age of 28 Days or When Full Enteral Nutrition is Achieved, Whichever is Longer. — 39; 45 participants who developed Cholestasis
N/A N=30 Intra-Abdominal Hypertension in Neonatal Intensive Care Patients
Intra-Abdominal Hypertension
Primary: Intra-abdominal Pressure(IAP) Measurements in NICU Patients. — 1219 IAP measurements
N/A N=121 Procalcitonin-Guided Decision Making to Shorten Antibiotic Therapy in Suspected Neonatal Early-Onset Sepsis
Sepsis
Primary: Antibiotic Treatment for More Than 72 Hours — 33; 55 participants — p=0.002
N/A N=162 Evaluation of Blood Glucose Monitoring Systems With Blood Samples From Neonates
Diabetes
Primary: Percent of Blood Glucose Results Within +/-15 mg/dL(<75 mg/dL) and Within +/-20% (>=75 mg/dL) of the Reference Instrument BG Value — 100.0; 99.5; 99.5 percentage of…
N/A N=120 Evaluation of the Performance of CONTOUR NEXT® and CONTOUR PLUS ELITE® BGMS in Neonates Using Capillary Blood Samples
Diabetes Mellitus
Primary: Number of Results From the Contour Next BGMSs Reference Values Within ±12.5% of Reference Values — 240 blood samples
Phase 2 N=18 Pharmacokinetic and Safety Trial of Intravenous Levetiracetam in the Treatment of Neonatal Seizures
Seizures · Disorder of Fetus or Newborn
Primary: Drug Clearance — 0.71; 1.31 ml/min/kg
Phase 2 N=28 Mild Encephalopathy in the Newborn Treated With Darbepoetin
Neonatal Encephalopathy · Hypoxic-Ischemic Encephalopathy Mild
Primary: Normal Neurodevelopment — 13; 14 Participants
N/A N=111 Cerebral Oxygenation and Autoregulation in Preterm Infants
Intraventricular Hemorrhage of Prematurity · Complications of Prematurity
Primary: Mortality Before Hospital Discharge — 11 Participants